Cargando…
Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma?
Autores principales: | Wang, Jun, Hui, Zhouguang, Pang, Qingsong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626336/ https://www.ncbi.nlm.nih.gov/pubmed/36214057 http://dx.doi.org/10.1111/1759-7714.14641 |
Ejemplares similares
-
Reply: Bayesian analysis supports the role of neoadjuvant chemoradiation followed by surgery for resectable locoregional esophageal cancer
por: Bao, Yongxing, et al.
Publicado: (2022) -
Adjuvant immunotherapy in resected esophageal squamous cell carcinoma: a gospel to the non-pCRs
por: Zhang, Zhihui, et al.
Publicado: (2021) -
Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone?
por: Lee, Kuan-Yu, et al.
Publicado: (2023) -
Survival of Neoadjuvant and Adjuvant Therapy Compared With Surgery Alone for Resectable Esophageal Squamous Cell Carcinoma: A Systemic Review and Network Meta-Analysis
por: Ma, Zeliang, et al.
Publicado: (2021) -
Immunotherapy for Esophageal Squamous Cell Carcinoma
por: Kojima, Takashi, et al.
Publicado: (2017)